• 1
    Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:124.
  • 2
    WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, Bright R, Shay D et al. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005–06 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55:4446.
  • 3
    U.S. Centers for Disease Control and Prevention (CDC). CDC Health Advisory: CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008–09 influenza season. Available at (Accessed 22 September 2011).
  • 4
    Le MT, Wertheim HF, Nguyen HD et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 2008; 3:e3339.
  • 5
    U.S. Centers for Disease Control and Prevention (CDC). Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Available at (Accessed 22 September 2011).
  • 6
    Baggs J, Gee J, Lewis E et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127(Suppl 1):S45S53.
  • 7
    Coleman LA, Kieke B, Irving S et al. Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine 2011; 29:387390.
  • 8
    U.S. Centers for Disease Control and Prevention (CDC). 2011–2012 influenza antiviral medications: summary for clinicians. Available at (Accessed 22 September 2011).
  • 9
    Genentech. Tamiflu (oseltamivir phosphate) Capsules and for Oral Suspension [Package insert]. South San Francisco, CA: Genentech USA, Inc, 2011. Available at (Accessed 7 March 2012).
  • 10
    GlaxoSmithKline. Relenza (Zanamivir for Inhalation) [Package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2011, Available at (Accessed 7 March 2012).
  • 11
    Roche Laboratories, Inc. Roche Prioritizes Production of Tamiflu® 75 mg Capsules (oseltamivir phosphate) to Provide Alternative to Limited Supplies of Tamiflu® for Oral Suspension (Oseltamivir Phosphate) and Tamiflu® 30 mg and 45 mg Capsules. Nutley, NJ: Roche Laboratories, Inc, 2009. Available at (Accessed 22 September 2011)
  • 12
    Ortiz JR, Kamimoto L, Aubert RE et al. Oseltamivir prescribing in pharmacy-benefits database, United States, 2004–2005. Emerg Infect Dis 2008; 14:12801283.
  • 13
    U.S. Department of Health and Human Services (HHS). HHS region map. Available at (Accessed 6 September 2011).
  • 14
    US Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children--Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:400402.
  • 15
    U.S. Centers for Disease Control and Prevention (CDC). Update: influenza activity – United States, August 30, 2009-March 27, 2010, and composition of the 2010–11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010; 59:423430.
  • 16
    Lee GM, Greene SK, Weintraub ES et al. H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project. Am J Prev Med 2011; 41:121128.
  • 17
    Marsden-Haug N, Foster VB, Gould PL, Elbert E, Wang H, Pavlin JA. Code-based syndromic surveillance for influenzalike illness by International Classification of Diseases, Ninth Revision. Emerg Infect Dis 2007; 13:207216.
  • 18
    Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:19351944.
  • 19
    Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302:18961902.
  • 20
    Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 4(Suppl):e91e97.
  • 21
    Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:15171525.
  • 22
    U.S. Food and Drug Administration (FDA). Emergency use of Tamiflu in infants less than 1 year of age. Available at (Accessed 21 September 2011).
  • 23
    Jernigan DB, Lindstrom SL, Johnson JR et al. Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clin Infect Dis 2011; 52(Suppl 1):S36S43.
  • 24
    Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. Am J Obstet Gynecol 2011; 204:S64S68.
  • 25
    Baxter R. Surveillance lessons from first-wave pandemic (H1N1) 2009, Northern California, USA. Emerg Infect Dis 2010; 16:504506.
  • 26
    Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA 1969; 208:11681170.
  • 27
    Schapira M. Treating multiple sclerosis with amantadine hydrochloride. J R Coll Gen Pract 1974; 24:411412.
  • 28
    Donfrancesco R, Calderoni D, Vitiello B. Open-label amantadine in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17:657664.
  • 29
    Lucetti C, Gambaccini G, Bernardini S et al. Amantadine in Huntington’s disease: open-label video-blinded study. Neurol Sci 2002; 23(Suppl 2):S83S84.